Carnitine supplementation as a therapy to improve insulin sensitivity in Type 2 diabetic patients with low carnitine status - Carnitine supplementation and insulin sensitivity

Maastricht University0 个研究点目标入组 36 人开始时间: 2017年8月29日最近更新: 2020年11月3日

试验速览

暂无简介。

•Men and woman
•Age: 40-70 years
•Woman should be postmenopausal
•BMI: 25-35 kg/m2
•Stable dietary habits
•No use of medication interfering with investigated study parameters (as determined by responsible physician)
•Use of oral glucose lowering medication (metformin only or in combination with sulfonylurea agents)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 36
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 36

•Haemoglobin levels < 7.8 mmol/L •Uncontrolled hypertension •Use of anticoagulants •Insulin dependent type 2 diabetic patients. •No signs of active liver or kidney malfunction. •Engagement in exercise > 3 hours a week •Being vegetarian or vegan (because of altered whole body carnitine status) •Alcohol and/or drug abuse •Unstable body weight (weight gain or loss > 5kg in the last 3 months) •Significant food allergies/intolerances (seriously hampering study meals) •Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results •Medication use known to hamper subject's safety during the study procedures •Subjects with contra-indications for MRI •Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study •Subjects who do not want to be informed about unexpected medical findings •No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy

发起方